Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Supplementary Materials of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (11119)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Feb 15, 2020 (publication date) through Apr 24, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastrointestinal Oncology
ISSN
1948-5204
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Cho IR, Kang H, Jo JH, Lee HS, Chung MJ, Park JY, Park SW, Song SY, An C, Park MS, Bang S. FOLFIRINOX vs gemcitabine/nab-paclitaxel for treatment of metastatic pancreatic cancer: Single-center cohort study. World J Gastrointest Oncol 2020; 12(2): 182-194 [PMID: 32104549 DOI: 10.4251/wjgo.v12.i2.182] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5204/full/v12/i2/182.htm |
| Number | Citing Articles |
| 1 |
Peter Holzhauer. Ein langer Weg: metastasierendes Pankreaskarzinom/COVID-19-Infektion und protrahiertes Fatigue-Syndrom. Deutsche Zeitschrift für Onkologie 2021; 53(01): 28 doi: 10.1055/a-1253-4409
|
| 2 |
Steve Robatel, Mirjam Schenk. Current Limitations and Novel Perspectives in Pancreatic Cancer Treatment. Cancers 2022; 14(4): 985 doi: 10.3390/cancers14040985
|
| 3 |
Gunn Huh, Hee Seung Lee, Jin Ho Choi, Sang Hyub Lee, Woo Hyun Paik, Ji Kon Ryu, Yong-Tae Kim, Seungmin Bang, Eaum Seok Lee. Gemcitabine plus Nab-paclitaxel as a second-line treatment following FOLFIRINOX failure in advanced pancreatic cancer: a multicenter, single-arm, open-label, phase 2 trial. Therapeutic Advances in Medical Oncology 2021; 13: 175883592110561 doi: 10.1177/17588359211056179
|
| 4 |
Devon J. Boyne, Darren R. Brenner, Alind Gupta, Eric Mackay, Paul Arora, Radek Wasiak, Winson Y Cheung, Miguel A. Hernán. Head-to-head comparison of FOLFIRINOX versus gemcitabine plus nab-paclitaxel in advanced pancreatic cancer: a target trial emulation using real-world data. Annals of Epidemiology 2023; 78: 28 doi: 10.1016/j.annepidem.2022.12.005
|
| 5 |
Mike Nguyen, Eva Segelov, David Goldstein, Nick Pavlakis, Jeremy Shapiro, Timothy J Price, Adnan Nagrial, Lorraine Chantrill, Trevor Leong, John Chen, Matt Burge, Christos S Karapetis, Ian Chau, Florian Lordick, Daniel Renouf, Niall Tebbutt, Amitesh C. Roy. Update on optimal management for pancreatic cancer: expert perspectives from members of the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty. Expert Review of Anticancer Therapy 2022; 22(1): 39 doi: 10.1080/14737140.2022.2002689
|
| 6 |
Jiyoung Keum, Hee Seung Lee, Jung Hyun Jo, Moon Jae Chung, Jeong Youp Park, Seung Woo Park, Si Young Song, Seungmin Bang. Impact of UGT1A1 Polymorphisms on Febrile Neutropenia in Pancreatic Cancer Patients Receiving FOLFIRINOX: A Single-Center Cohort Study. Cancers 2022; 14(5): 1244 doi: 10.3390/cancers14051244
|
| 7 |
Celine Yeh, Susan E. Bates. Two decades of research toward the treatment of locally advanced and metastatic pancreatic cancer: Remarkable effort and limited gain. Seminars in Oncology 2021; 48(1): 34 doi: 10.1053/j.seminoncol.2021.01.001
|
| 8 |
Keun-Yeong Jeong, Min Hee Park. The Significance of Targeting Poly (ADP-Ribose) Polymerase-1 in Pancreatic Cancer for Providing a New Therapeutic Paradigm. International Journal of Molecular Sciences 2021; 22(7): 3509 doi: 10.3390/ijms22073509
|
| 9 |
Vikrant Rai, Swati Agrawal. Targets (Metabolic Mediators) of Therapeutic Importance in Pancreatic Ductal Adenocarcinoma. International Journal of Molecular Sciences 2020; 21(22): 8502 doi: 10.3390/ijms21228502
|
| 10 |
Sung Yong Han, Dong Uk Kim, Young Mi Seol, Suk Kim, Nam Kyung Lee, Seung Baek Hong, Hyung-Il Seo. Comparison of gemcitabine plus nab-paclitaxel and FOLFIRINOX in metastatic pancreatic cancer. World Journal of Clinical Cases 2020; 8(17): 3718-3729 doi: 10.12998/wjcc.v8.i17.3718
|
| 11 |
Rai Shimoyama, Yoshinori Imamura, Kiyoaki Uryu, Takahiro Mase, Yoshiaki Fujimura, Maki Hayashi, Megu Ohtaki, Keiko Ohtani, Nobuaki Shinozaki, Hironobu Minami. Real‑world treatment outcomes among patients with metastatic pancreatic cancer in Japan: The Tokushukai real‑world data project. Molecular and Clinical Oncology 2023; 19(6) doi: 10.3892/mco.2023.2694
|
| 12 |
Mugahed Abdullah Hasan Albahde, Bulat Abdrakhimov, Guo-Qi Li, Xiaohu Zhou, Dongkai Zhou, Hao Xu, Huixiao Qian, Weilin Wang. The Role of Microtubules in Pancreatic Cancer: Therapeutic Progress. Frontiers in Oncology 2021; 11 doi: 10.3389/fonc.2021.640863
|
| 13 |
Hao Ma, Yuelin Wu, Wannian Zhang, Huojun Zhang, Zhenyuan Miao, Chunlin Zhuang. Radiosensitization of human pancreatic cancer by piperlongumine analogues. Chinese Chemical Letters 2021; 32(3): 1197 doi: 10.1016/j.cclet.2020.08.049
|
| 14 |
A. Gueiderikh, A. Tarabay, M. Abdelouahab, C. Smolenschi, M. L. Tanguy, M. Valery, D. Malka, T. Pudlarz, A. Fuerea, V. Boige, A. Hollebecque, M. Ducreux, A. Boilève. Pancreatic adenocarcinoma third line systemic treatments: a retrospective cohort study. BMC Cancer 2024; 24(1) doi: 10.1186/s12885-024-12016-z
|
| 15 |
Jakob M. Riedl, Florian Posch, Lena Horvath, Antonia Gantschnigg, Felix Renneberg, Esther Schwarzenbacher, Florian Moik, Dominik A. Barth, Christopher H. Rossmann, Michael Stotz, Renate Schaberl-Moser, Martin Pichler, Herbert Stöger, Richard Greil, Angela Djanani, Konstantin Schlick, Armin Gerger. Gemcitabine/nab-Paclitaxel versus FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysis. European Journal of Cancer 2021; 151: 3 doi: 10.1016/j.ejca.2021.03.040
|
| 16 |
Takafumi Mie, Takashi Sasaki, Tsuyoshi Takeda, Takeshi Okamoto, Tsuyoshi Hamada, Takahiro Ishitsuka, Manabu Yamada, Hiroki Nakagawa, Takaaki Furukawa, Akiyoshi Kasuga, Masato Matsuyama, Masato Ozaka, Naoki Sasahira. Treatment Outcomes and Prognostic Factors of Gemcitabine Plus Nab-Paclitaxel as Second-Line Chemotherapy after Modified FOLFIRINOX in Unresectable Pancreatic Cancer. Cancers 2023; 15(2): 358 doi: 10.3390/cancers15020358
|
| 17 |
Hiroki Irie, Rei Suzuki, Yoshinori Okubo, Hiroyuki Asama, Naoki Konno, Yuki Noguchi, Ko Watanabe, Goro Shibukawa, Hidemichi Imamura, Tadayuki Takagi, Mitsuru Sugimoto, Yuki Sato, Jun Nakamura, Tsunetaka Kato, Minami Hashimoto, Takumi Yanagita, Takuto Hikichi, Hiromasa Ohira. Clinical benefit of subsequent chemotherapy after drug-induced interstitial lung disease in pancreatic cancer patients: a multicenter retrospective study from Japan. BMC Cancer 2023; 23(1) doi: 10.1186/s12885-023-10781-x
|
| 18 |
Byung Soo Kwan, Ok Jae Lee, Hyun Jin Kim, Kwang Min Kim, Sang Goon Shim, Dae Hyeon Cho, Sung Min Kong, Jun Young Kim, Jun Ho Ji. Efficacy and Safety of Chemotherapy in Elderly Patients with Unresectable Pancreatic Cancer. Journal of Clinical Medicine 2023; 12(9): 3334 doi: 10.3390/jcm12093334
|
| 19 |
Hoon Jai Chun, Seun Ja Park, Yun Jeong Lim, Si Young Song. Gastrointestinal Cancer. 2023; : 351 doi: 10.1007/978-981-99-0815-8_51
|
| 20 |
Kexin Li, Qingji Huo, Kazumasa Minami, Keisuke Tamari, Kazuhiko Ogawa, Sungsoo Na, Melissa L. Fishel, Bai-Yan Li, Hiroki Yokota. Exploring the Tumor-Suppressing Potential of PSCA in Pancreatic Ductal Adenocarcinoma. Cancers 2023; 15(20): 4917 doi: 10.3390/cancers15204917
|
| 21 |
Francesca Foschini, Fabiana Napolitano, Alberto Servetto, Roberta Marciano, Eleonora Mozzillo, Anna Chiara Carratù, Antonio Santaniello, Pietro De Placido, Priscilla Cascetta, Giovanni Butturini, Isabella Frigerio, Paolo Regi, Nicola Silvestris, Sabina Delcuratolo, Enrico Vasile, Caterina Vivaldi, Cataldo Bianco, Sabino De Placido, Luigi Formisano, Roberto Bianco. FOLFIRINOX after first-line gemcitabine-based chemotherapy in advanced pancreatic cancer: a retrospective comparison with FOLFOX and FOLFIRI schedules. Therapeutic Advances in Medical Oncology 2020; 12: 175883592094797 doi: 10.1177/1758835920947970
|
| 22 |
Takafumi Mie, Takashi Sasaki, Tsuyoshi Takeda, Koshiro Fukuda, Takaaki Furukawa, Yuto Yamada, Akiyoshi Kasuga, Masato Matsuyama, Masato Ozaka, Naoki Sasahira. Comparison of Treatment Outcomes Between Gemcitabine With Nab-Paclitaxel and Modified FOLFIRINOX for First-Line Chemotherapy in Metastatic and Recurrent Pancreatic Cancer. Pancreas 2021; 50(4): 595 doi: 10.1097/MPA.0000000000001801
|
| 23 |
Jung Won Chun, Sang Hyub Lee, Joo Seong Kim, Namyoung Park, Gunn Huh, In Rae Cho, Woo Hyun Paik, Ji Kon Ryu, Yong-Tae Kim. Comparison between FOLFIRINOX and gemcitabine plus nab-paclitaxel including sequential treatment for metastatic pancreatic cancer: a propensity score matching approach. BMC Cancer 2021; 21(1) doi: 10.1186/s12885-021-08277-7
|
| 24 |
Marwa Elsayed, Maen Abdelrahim. The Latest Advancement in Pancreatic Ductal Adenocarcinoma Therapy: A Review Article for the Latest Guidelines and Novel Therapies. Biomedicines 2021; 9(4): 389 doi: 10.3390/biomedicines9040389
|
| 25 |
Kwangrok Jung, Suhyun Choi, Hyunjoo Song, Kyuhan Kwak, Soyeon Anh, Jae Hyup Jung, Bomi Kim, Jinwoo Ahn, Jaihwan Kim, Jin-Hyeok Hwang, Jong-chan Lee. Real-world dose reduction of standard and modified FOLFIRINOX in metastatic pancreatic cancer: a systematic review, evidence-mapping, and meta-analysis. Therapeutic Advances in Medical Oncology 2023; 15 doi: 10.1177/17588359231175441
|
| 26 |
In Rae Cho. Treatment Outcome of Matched Therapy after Molecular Profiling in Patients with Advanced Pancreatic Cancer. The Korean Journal of Gastroenterology 2020; 76(3): 174 doi: 10.4166/kjg.2020.76.3.174
|
| 27 |
Qian Wang, Zihua Wang, Zhangfu Li, Dan Li, Fangfei He, Kun Wang, Jie Tian, Xinming Zhao. Biomimetic camouflaged nanoparticle-based folfirinox platform for optimizing clinical pancreatic cancer treatment. Nano Today 2023; 48: 101733 doi: 10.1016/j.nantod.2022.101733
|
| 28 |
Roberta Romano, Anna Picca, Leonardo Henry Umberto Eusebi, Emanuele Marzetti, Riccardo Calvani, Loredana Moro, Cecilia Bucci, Flora Guerra. Extracellular Vesicles and Pancreatic Cancer: Insights on the Roles of miRNA, lncRNA, and Protein Cargos in Cancer Progression. Cells 2021; 10(6): 1361 doi: 10.3390/cells10061361
|
| 29 |
Wungki Park, Catherine A. O'Connor, Chaitanya Bandlamudi, Daniella Forman, Joanne F. Chou, Shigeaki Umeda, Marsha Reyngold, Anna M. Varghese, Fergus Keane, Fiyinfolu Balogun, Kenneth H. Yu, David P. Kelsen, Christopher Crane, Marinela Capanu, Christine Iacobuzio-Donahue, Eileen M. O'Reilly. Clinico-genomic Characterization of ATM and HRD in Pancreas Cancer: Application for Practice. Clinical Cancer Research 2022; 28(21): 4782 doi: 10.1158/1078-0432.CCR-22-1483
|
| 30 |
Magdalena Zaremba-Czogalla, Anna Jaromin, Katarzyna Sidoryk, Agnieszka Zagórska, Marcin Cybulski, Jerzy Gubernator. Evaluation of the In Vitro Cytotoxic Activity of Caffeic Acid Derivatives and Liposomal Formulation against Pancreatic Cancer Cell Lines. Materials 2020; 13(24): 5813 doi: 10.3390/ma13245813
|
| 31 |
Yoon Suk Lee, Jong-chan Lee, Jae-Hyeong Kim, Jaihwan Kim, Jin-Hyeok Hwang. Pharmacoethnicity of FOLFIRINOX versus gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: a systematic review and meta-analysis. Scientific Reports 2021; 11(1) doi: 10.1038/s41598-021-99647-5
|
| 32 |
Rituraj Chakraborty, Anupam Dutta, Bhargab Jyoti Baruah, Rajni Kumari, Priyanku Sarma, Ankita Sharma, Krishangi Goswami, Haritha Myakala, Akalesh Kumar Verma. Pancreatic Cancer: A Review on Pathophysiology, Naturopathy, Clinical
Treatment and Outcomes. Current Cancer Therapy Reviews 2024; 20(3): 263 doi: 10.2174/1573394719666230830125213
|
| 33 |
Christina Jane Vellan, Jaime Jacqueline Jayapalan, Boon-Koon Yoong, Azlina Abdul-Aziz, Sarni Mat-Junit, Perumal Subramanian. Application of Proteomics in Pancreatic Ductal Adenocarcinoma Biomarker Investigations: A Review. International Journal of Molecular Sciences 2022; 23(4): 2093 doi: 10.3390/ijms23042093
|
| 34 |
Silvia Di Giacomo, Marco Gullì, Roberta Facchinetti, Marco Minacori, Romina Mancinelli, Ester Percaccio, Caterina Scuderi, Margherita Eufemi, Antonella Di Sotto. Sorafenib Chemosensitization by Caryophyllane Sesquiterpenes in Liver, Biliary, and Pancreatic Cancer Cells: The Role of STAT3/ABC Transporter Axis. Pharmaceutics 2022; 14(6): 1264 doi: 10.3390/pharmaceutics14061264
|
| 35 |
Adam Markowski, Paweł Migdał, Adrianna Zygmunt, Magdalena Zaremba-Czogalla, Jerzy Gubernator. Evaluation of the In Vitro Cytotoxic Activity of Ursolic Acid PLGA Nanoparticles against Pancreatic Ductal Adenocarcinoma Cell Lines. Materials 2021; 14(17): 4917 doi: 10.3390/ma14174917
|
| 36 |
Min Je Sung, Seungmin Bang. Updates of Chemotherapy and Radiotherapy for Pancreatic Cancer. The Korean Journal of Pancreas and Biliary Tract 2020; 25(2): 72 doi: 10.15279/kpba.2020.25.2.72
|
| 37 |
Hussein H. Khachfe, Joseph R. Habib, Ibrahim Nassour, Salem Al Harthi, Faek R. Jamali. Borderline Resectable and Locally Advanced Pancreatic Cancers. Pancreas 2021; 50(9): 1243 doi: 10.1097/MPA.0000000000001924
|
| 38 |
Min Je Sung. Updates of Chemotherapy for Pancreatic Cancer. Journal of Digestive Cancer Research 2023; 11(3): 147 doi: 10.52927/jdcr.2023.11.3.147
|
| 39 |
Angelo Borsarelli Carvalho de Brito, Rachel P Riechelmann, Victor Hugo Fonseca de Jesus. Impact of Granulocyte Colony-Stimulating Factor (G-CSF) on the Outcomes of Patients With Metastatic Pancreatic Adenocarcinoma (MPA) During First-Line Treatment With FOLFIRINOX: A Single-Center Retrospective Analysis. Cancer Control 2023; 30: 107327482211495 doi: 10.1177/10732748221149543
|
| 40 |
Alycia Hatashima, Matthew J Arango, Joshua Reardon, Tracelyn Freeman, Terence Williams, Eric M McLaughlin, Laith Abushahin. First-line gemcitabine plus nab-paclitaxel versus FOLFIRINOX for metastatic pancreatic cancer in a real-world population. Future Oncology 2022; 18(20): 2521 doi: 10.2217/fon-2021-1367
|